AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the Company’s drug Ampligen^® in the treatment of endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States.